BioNTech SE (BNTX) Common Equity (2018 - 2025)

BioNTech SE (BNTX) has 8 years of Common Equity data on file, last reported at $22.4 billion in Q4 2025.

• For the quarter ending Q4 2025, Common Equity rose 7.88% year-over-year to $22.4 billion; the trailing twelve-month figure through Dec 2025 stood at $22.4 billion (up 7.88% YoY), and the FY2025 full-year result was $21.7 billion, up 4.71% from the prior year.
• Common Equity advanced to $22.4 billion in Q4 2025, from $21.6 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $22.4 billion in Q4 2025 to a low of $3.0 billion in Q1 2021.
• A 5-year average of $18.2 billion and a median of $20.6 billion in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 895.88% in 2021 and declined 8.22% in 2025, its largest moves.
• Tracing BNTX's Common Equity over 5 years: stood at $13.6 billion in 2021, then soared by 50.39% to $20.5 billion in 2022, then grew by 6.46% to $21.8 billion in 2023, then slipped by 4.78% to $20.7 billion in 2024, then advanced by 7.88% to $22.4 billion in 2025.
• Business Quant data shows BNTX's Common Equity at $22.4 billion in Q4 2025, $21.6 billion in Q3 2025, and $20.9 billion in Q2 2025.